Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amivantamab + monochemotherapy
- Development stage
- Unknown
- Lead developer
- Janssen Biotech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
Amivantamab + monochemotherapy is a combination regimen being evaluated in the Phase II AMICUTE trial (sponsored by Fondazione Ricerca Traslazionale) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations who are unfit for platinum-based chemotherapy. Amivantamab (Rybrevant) is a fully human bispecific antibody that targets both the epidermal growth factor receptor (EGFR) and the mesenchymal-epithelial transition (MET) receptor. Its mechanism involves blocking ligand binding, promoting receptor degradation, and inducing immune-mediated effects such as antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis. In this specific clinical context, amivantamab is administered subcutaneously in combination with an investigator's choice of monochemotherapy, either pemetrexed or gemcitabine, which are antimetabolite small molecules that inhibit DNA synthesis. This combination aims to provide an effective and tolerable alternative for patients who cannot undergo standard platinum-based doublet chemotherapy.
- Brand names
- RybrevantAlimtaGemzar
- Other names
- JNJ-61186372JNJ61186372JNJ 61186372LY231514LY-231514LY 231514LY188011LY-188011LY 188011amivantamab + pemetrexedamivantamab + gemcitabine
02
Targets
DNARNR (Ribonucleotide reductase)Epidermal growth factor receptor–Hepatocyte growth factor receptor extracellular interfaceEGFR T790M (Epidermal growth factor receptor T790M mutant)DHFR (Dihydrofolate reductase)MET (Mesenchymal-epithelial transition factor receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on amivantamab + monochemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amivantamab + monochemotherapy.